Twist Bioscience Co. (NASDAQ:TWST) Shares Bought by Cwm LLC

Cwm LLC lifted its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 141.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,894 shares of the company’s stock after purchasing an additional 3,457 shares during the quarter. Cwm LLC’s holdings in Twist Bioscience were worth $266,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Baillie Gifford & Co. raised its stake in shares of Twist Bioscience by 12.1% during the 1st quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock worth $42,116,000 after buying an additional 132,770 shares during the period. Point72 Asset Management L.P. increased its holdings in Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after acquiring an additional 613,057 shares in the last quarter. Fred Alger Management LLC raised its position in Twist Bioscience by 720.7% during the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after acquiring an additional 575,080 shares during the period. Driehaus Capital Management LLC lifted its holdings in Twist Bioscience by 63.0% during the second quarter. Driehaus Capital Management LLC now owns 388,643 shares of the company’s stock valued at $19,152,000 after purchasing an additional 150,260 shares in the last quarter. Finally, Ensign Peak Advisors Inc lifted its holdings in Twist Bioscience by 74.6% during the second quarter. Ensign Peak Advisors Inc now owns 331,373 shares of the company’s stock valued at $16,330,000 after purchasing an additional 141,557 shares in the last quarter.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 856 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the sale, the chief financial officer now owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Twist Bioscience news, SVP Paula Green sold 1,137 shares of Twist Bioscience stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $39.93, for a total transaction of $45,400.41. Following the completion of the sale, the senior vice president now directly owns 88,837 shares in the company, valued at $3,547,261.41. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Adam Laponis sold 856 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $41.81, for a total transaction of $35,789.36. Following the completion of the sale, the chief financial officer now directly owns 73,397 shares in the company, valued at $3,068,728.57. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,039 shares of company stock worth $1,704,396 in the last 90 days. Insiders own 3.92% of the company’s stock.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $45.35 on Tuesday. The business’s 50 day moving average price is $44.03 and its 200 day moving average price is $44.55. The company has a market cap of $2.64 billion, a price-to-earnings ratio of -13.50 and a beta of 1.77. Twist Bioscience Co. has a one year low of $14.42 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The firm had revenue of $81.50 million for the quarter, compared to analyst estimates of $77.40 million. During the same period in the previous year, the firm posted ($1.01) EPS. The company’s revenue was up 27.7% compared to the same quarter last year. On average, analysts predict that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on TWST shares. JPMorgan Chase & Co. upped their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. Robert W. Baird increased their target price on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. Barclays decreased their target price on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Leerink Partners boosted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, The Goldman Sachs Group raised their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of “Moderate Buy” and an average target price of $51.22.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.